Navigation Links
Gene Thought to Help Kill Cancer Cells may Actually Help Them Thrive

A new study of chemo patients, scientists at the Georgia Institute of Technology and the Ovarian Cancer Institute has revealed that a gene , p53, thought to be essential in helping chemotherapy kill cancer cells, may actually help them thrive.

The researchers found that 70 percent of subjects whose tumors had mutations in the gene p53 were still alive after five years. Patients with normal p53 displayed only a 30 percent survival rate.

The findings raise the possibility of a new strategy for fighting cancer - namely, developing drugs to disable the functioning of this gene in the tumors of patients undergoing chemotherapy.

P53 has long been recognized as a key player in directing chemotherapy-damaged cancer cells to self annihilate, but less attention has been paid to p53s role in repairing damaged cells, said John McDonald, chair of Georgia Techs School of Biology and chief research scientist at the Ovarian Cancer Institute.

Georgia Tech researchers found that p53 may be a double-edged sword. Chemotherapy patients whose tumors had a mutated p53 gene that didn't work had a much better survival rate than those who had normal p53.

In the study, researchers took malignant and benign ovarian tumors straight from the operating room and compared their gene expression profiles. Some of the cancer patients had been treated with chemotherapy prior to surgery, and some had not. At this point researchers didn't consider whether the patients actually had malignant tumors or had been treated with chemotherapy.

However, they found that the gene expression profiles of the tumors clustered the chemotherapy-treated patients into two groups: those whose profiles were similar to cancer patients who had not been treated with chemo and those whose profiles were similar to patients with benign tumors.

As they continued their analysis, they found that the main difference between the groups' genetic profiles was the gene p53. While both groups had roughly the same amount of the protein encoded by p53, the cancer group had mutations in their p53 that caused the genes corresponding protein not to function. The benign group's p53 was normal.

Five years later, only 30 percent of the chemotherapy cancer patients clustering in the benign group were alive, while 70 percent of those clustering in the cancer group were still alive. The stage of cancer at the time of surgery had no correlation to who survived and who didn't. What did seem to have an effect was whether p53 was working or not in the chemotherapy-treated tumors.

A standard belief in cancer research is that a working p53 is essential in helping chemo patients because it turns on the killing mechanism for the cells that were damaged by chemo. But McDonald points out that p53 can also help repair damaged cells. If p53 is repairing cancer cells, that may lead to cancer recurrence.

"We think p53 may actually help some cancer cells make a comeback, he said. "Based on our results, we propose that p53 may help repair some of the cancer cells damaged by chemotherapy leading to tumor recurrence and explaining the higher mortality rate of patients whose tumors had a functioning p53. If we are correct, inhibiting p53 in tumors being treated with chemotherapy may substantially improve patients' long-term survival."

McDonald and colleagues are continuing to test their theory by conducting studies in cell cultures and mice. If it bears out, then disabling the gene in tumors, through medications or new genetic techniques during chemotherapy may help patients survive.

The study appears in the May 16 edition of the open access journal PloS.


'"/>




Related medicine news :

1. Genetic Pills A Future Thought
2. Antidepressant Medication Leading To Suicidal Thoughts
3. Soy Benefits May Not Be As Much As Thought Before
4. Mice With Human Thought Processes Could Be Developed In The Future
5. HPV Thought To Be a Culprit in Skin Cancer
6. High Spirits :Second Thoughts on the Mini Pegs
7. Death Pumps Up Aggressive Thoughts
8. Japanese Scientists Develop Thought-Controlled Robotic Hands
9. Scientists Develop Thought-Controlled Robotic Hands
10. Inculcating Positive Thoughts Could Eliminate Depressive Mood
11. Obesity Surgery Complication Rates Higher than Previously Thought
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Sharon Kleyne, ... the air to educate listeners about the benefits of making new water infrastructure a ... Kleyne said, “it’s appropriate that we expect water infrastructure to become a top priority ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement ... the right method is paramount to success. Selecting an inappropriate measurement method can ... multiple persons use the same equipment. Rare or expensive substances are wasted and ...
(Date:1/23/2017)... Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of ... camera to create dynamic looks in Final Cut Pro X," said Christina Austin - CEO ... of up to two layers of text with video footage. ProRandom works by using ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- The global peripheral I.V. catheter market accounted for ... to grow at a CAGR of 6.0% during 2016-2022. ... share in the global market between the two types ... hospital segment accounted for the highest share in the ... I.V. catheter market is witnessing high growth rate, due ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES ... rights to develop and commercialize nuc -gemcitabine™ ... a Korean pharmaceutical company. nuc ... aptamer against surface nucleolin found on many cancer ... Unlike ADCs (antibody drug conjugates) or SMDCs (small ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology: